Search Results

Many falls in older adults happen when people bump into or are struck by objects they did not see in time. This study looks at how we use what we see straight ahead and out of the corner of the eye to keep our balance when objects move toward us, and how this changes as we age. Healthy adults aged 20 to 80 will complete short computer-based vision tests and then, while standing in a safety harness, use a robotic handle to stop virtual moving objects or reach toward targets on a screen. During these tasks, we will record eye movements, muscle activity, and body sway to see how well the body prepares for and reacts to contact. The results may help guide future programs to prevent falls in older adults.

Participants will make one in-person visit of about 2 hours (Experiment 1) or two visits of about 2 hours each (Experiments 2 and 3). They will do short computer vision tests, have small sensors taped to the arm and legs, and stand in a safety harness while using a robotic handle to stop virtual moving objects or reach toward targets. No blood or samples will be collected.

$20-40

This research study examines how human voice patterns relate to respiratory health and sleeping disorders. Participants will attend two short visits at Penn State. During the visits, they will record their voice, answer a few questions, give a saliva sample, and have a 3D image of their face taken during the session. The goal is to help researchers learn whether voice patterns can help study respiratory and sleep-related health.

Participants will complete two study visits. They will answer short questionnaires and provide 3D facial images, a saliva sample for one time only, and brief voice recordings during each visit.

$25

This study will ask healthcare professionals who care for children with cancer about their views of pediatric oncology clinical trials. An online survey will explore how they think families experience these trials, including their goals, hopes, expectations, concerns, and emotional challenges. The study will also ask about healthcare professionals’ knowledge, confidence, communication needs, and training related to clinical trials. The survey will take about 10 minutes, and up to 80 healthcare professionals may participate. The findings may help improve communication and support for families considering clinical trial participation.

Participants will complete a one-time online survey about their perspectives on pediatric oncology clinical trials. The survey will take approximately 10 minutes and may be completed remotely using a personalized link sent to their work email.

This research study includes two studies in one; a Phase 2 study and a Phase 3 study. The main goal of the Phase 2 study is to see if Brepocitinib is safe and if it works for adult participants who have active, moderate to severe lichen planopilaris (LPP). The main goal of the Phase 3 study is to see how well the treatment, Brepocitinib, works for those with LPP, in comparison to placebo (no active ingredient). Throughout the study, which lasts about 60 weeks, participants will complete questionnaires, have their LPP checked by the doctor, and undergo several procedures, including an EKG, a chest X‑ray, photographs, and blood tests.

Participants will be required to attend 13 in person visits. In addition, at week 4 participants will be required to stay for 1 hour after they take their study medicine to have their blood drawn.

The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with atrial fibrillation and a recent brain hemorrhage to see which is better at preventing future strokes and death.

This study is for patients who have had a recent brain bleed (hemorrhagic stroke) within the past six months and also have a history of afib. Participants will be randomized to either aspirin OR apixaban. The assigned medication will be provided free of cost to participants for the duration of study participation. There will be up to 13 study visits over the course of 2-3 years. The first visit MUST be in person, but some follow up visits can be conducted via phone if necessary. Blood will be collected at the first visit only. All visits will involve filling out questionnaires, collecting vitals, and reviewing medications and medical history.

$650

This study is assessing the safety and tolerability of a new investigational treatment for glioma brain cancer. The treatment, Bilateral Hemispheric 5-ALA–Mediated Sonodynamic Therapy, and referred to as Porphyrin Metabolite Activation (PoMA™), combines a oral drug with targeted ultrasound therapy.

Once you sign consent, there will be a screening visit which may include a CT scan, blood tests, and study assessments/exams. Once screening results have been confirmed, you will receive your first 2 treatments 5-ALA-mediated sonodynamic therapy using the LIDU System before standard radiochemotherapy. After your radiochemotherapy and during adjuvant Temozolomide, you will continue the study treatment once every 30 days for up to 4 additional cycles. Your participation will last approximately 24 months including long-term follow up.